XSHE
002019
Market cap2.18bUSD
Dec 05, Last price
12.66CNY
1D
-1.33%
1Q
-18.74%
Jan 2017
-17.20%
IPO
953.94%
Name
Yifan Pharmaceutical Co Ltd
Chart & Performance
P/E
39.90
P/S
2.98
EPS
0.32
Div Yield, %
0.79%
Shrs. gr., 5y
-0.24%
Rev. gr., 5y
-0.10%
Revenues
5.16b
+28.28%
Net income
386m
P
CFO
641m
+83.81%
Dividend
Sep 25, 20240.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yifan Pharmaceutical Co., Ltd. produces and sells drugs and medicines in China and internationally. It provides drugs across gynecology, pediatrics, orthopedics, and dermatology therapeutic areas; therapeutic infusion solutions; and pantothenic acid and Provitamin B5 products. The company also provides Chinese traditional medicines, women's health products, and blood tumor drugs. In addition, it offers APIs, including feed additives/animal health products, skin and hair care ingredients, functional food additives, and fine chemicals; and PBAT/PBS biodegradable resins and PVB films. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is based in Hangzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||